User: Guest  Login
Title:

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

Document type:
Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't
Author(s):
Yu, Evan Y; Kolinsky, Michael P; Berry, William R; Retz, Margitta; Mourey, Loic; Piulats, Josep M; Appleman, Leonard J; Romano, Emanuela; Gravis, Gwenaelle; Gurney, Howard; Bögemann, Martin; Emmenegger, Urban; Joshua, Anthony M; Linch, Mark; Sridhar, Srikala; Conter, Henry J; Laguerre, Brigitte; Massard, Christophe; Li, Xin Tong; Schloss, Charles; Poehlein, Christian H; de Bono, Johann S
Abstract:
BACKGROUND: Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enzalutamide and need more efficacious treatments. OBJECTIVE: To evaluate the efficacy and safety of pembrolizumab plus docetaxel and prednisone in patients with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: The trial included patients with mCRPC in the phase 1b/2 KEYNOTE-365 cohort B study who were chemotherapy naïve and who experienced failu...     »
Journal title abbreviation:
Eur Urol
Year:
2022
Journal volume:
82
Journal issue:
1
Pages contribution:
22-30
Fulltext / DOI:
doi:10.1016/j.eururo.2022.02.023
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35397952
Print-ISSN:
0302-2838
TUM Institution:
Klinik und Poliklinik für Urologie
 BibTeX